^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    CD137 agonist

    Related drugs:
    4d
    Safety, feasibility and pharmacodynamic activity of intratumoral injections of the agonist anti-CD137 (4-1BB) mAb urelumab in combination with nivolumab. (PubMed, Clin Cancer Res)
    Intratumoral delivery of urelumab is feasible, safe, and induces favorable immunopharmacodynamic effects in serial biopsies and in peripheral blood. Our results support the development of tumor-targeted next-generation CD137 (4-1BB) agonists.
    PK/PD data • Journal • PD(L)-1 Biomarker • IO biomarker
    |
    CD8 (cluster of differentiation 8)
    |
    Opdivo (nivolumab) • urelumab (BMS-663513)
    4d
    Study BT7480-100 in Patients With Advanced Malignancies Associated With Nectin-4 Expression (clinicaltrials.gov)
    P1/2, N=200, Active, not recruiting, BicycleTx Limited | Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: Sep 2025 --> Aug 2026
    Trial completion date • Trial primary completion date • First-in-human
    |
    NECTIN4 (Nectin Cell Adhesion Molecule 4)
    |
    Opdivo (nivolumab) • BT7480
    7d
    A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers (clinicaltrials.gov)
    P1/2, N=73, Terminated, Ocellaris Pharma, Inc. | Trial completion date: Sep 2026 --> Nov 2025 | Active, not recruiting --> Terminated | Trial primary completion date: Mar 2026 --> Nov 2025; Business Decision
    Trial completion date • Trial termination • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • ALK (Anaplastic lymphoma kinase) • PGR (Progesterone receptor) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    HER-2 negative • ALK fusion • ALK mutation • ROS1 fusion
    |
    Bavencio (avelumab) • OC-001
    7d
    Study of the Effectiveness and Safety of Acasunlimab Alone and With Pembrolizumab to Treat Advanced Melanoma of the Skin That Has Returned After Treatment With an Approved Checkpoint Inhibitor Therapy (ABBIL1TY MELANOMA-07) (clinicaltrials.gov)
    P2, N=1, Active, not recruiting, Genmab | N=90 --> 1
    Enrollment change • Checkpoint inhibition
    |
    BRAF (B-raf proto-oncogene)
    |
    BRAF mutation • BRAF V600
    |
    Keytruda (pembrolizumab) • acasunlimab (GEN1046)
    7d
    Trial to Evaluate Acasunlimab and Pembrolizumab Combination Superiority Over Standard of Care Docetaxel in Non-Small Cell Lung Cancer (ABBIL1TY NSCLC-06) (clinicaltrials.gov)
    P3, N=702, Active, not recruiting, Genmab | Recruiting --> Active, not recruiting
    Enrollment closed • Head-to-Head
    |
    PD-L1 expression
    |
    Keytruda (pembrolizumab) • docetaxel • acasunlimab (GEN1046)
    10d
    A Phase II Clinical Study of LBL-024 Combination Therapy in Patients With Advanced Solid Tumour[Substudy 03(ESCC)] (clinicaltrials.gov)
    P2, N=110, Not yet recruiting, Nanjing Leads Biolabs Co.,Ltd
    New P2 trial
    |
    cisplatin • paclitaxel • 5-fluorouracil • Tevimbra (tislelizumab-jsgr) • capecitabine
    11d
    ADG116-1003: A Phase 1b/2 Study of ADG116, ADG116 Combined With Anti-PD-1 Antibody or Anti-CD137 Antibody in Solid Tumors Patients (clinicaltrials.gov)
    P1, N=72, Completed, Adagene Inc | Active, not recruiting --> Completed | Trial completion date: Feb 2025 --> Nov 2025
    Trial completion • Trial completion date
    |
    Loqtorzi (toripalimab-tpzi) • ADG106
    11d
    Study of ADG206 in Subjects With Advanced/Metastatic Solid Tumors (clinicaltrials.gov)
    P1, N=14, Active, not recruiting, Adagene Inc | Recruiting --> Active, not recruiting | N=21 --> 14 | Trial completion date: Oct 2025 --> Aug 2026
    Enrollment closed • Enrollment change • Trial completion date • First-in-human
    12d
    A Study to Test DSP107 in Combination With Atezolizumab in Comparison With Fruquintinib as a New Treatment for Colorectal Cancer. (clinicaltrials.gov)
    P2, N=90, Recruiting, Kahr Bio Australia Pty Ltd | Not yet recruiting --> Recruiting
    Enrollment open
    |
    BRAF (B-raf proto-oncogene)
    |
    Tecentriq (atezolizumab) • Fruzaqla (fruquintinib) • DSP-107
    13d
    A Safety Trial of GEN1042 in Japanese Subjects With Malignant Solid Tumors (clinicaltrials.gov)
    P1, N=42, Active, not recruiting, Genmab | Trial primary completion date: Mar 2026 --> Nov 2026
    Trial primary completion date
    |
    Keytruda (pembrolizumab) • cisplatin • carboplatin • 5-fluorouracil • tecaginlimab (GEN1042)
    13d
    Utomilumab, Cetuximab, and Irinotecan Hydrochloride in Treating Patients With Metastatic Colorectal Cancer (clinicaltrials.gov)
    P1, N=34, Completed, M.D. Anderson Cancer Center | Trial completion date: Dec 2026 --> Dec 2025 | Trial primary completion date: Dec 2026 --> Dec 2025 | Active, not recruiting --> Completed
    Trial completion • Trial completion date • Trial primary completion date
    |
    MSI (Microsatellite instability)
    |
    MSI-H/dMMR • RAS mutation
    |
    Erbitux (cetuximab) • irinotecan • utomilumab (PF-05082566)
    22d
    A Study of AP601 in Patients With Locally Unresectable Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
    P1, N=36, Recruiting, AP Biosciences Inc. | Not yet recruiting --> Recruiting | Initiation date: Sep 2025 --> Jan 2026
    Enrollment open • Trial initiation date